Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Clinical trial NCT04566952 · UNKNOWN

Trial details

NCT number: NCT04566952
Sponsor: Xiaoxiang Chen
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Ovarian Cancer Ovarian and Fallopian Tube Cysts and Neoplasms Neoplasms by Site Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Carcinoma, Ovarian Epithelial Ovarian Diseases Adnexal Diseases Genital Diseases, Female

Start date: 2020-10-28
Primary completion: 2023-03-01
Enrollment: 68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.